PrimeVax Immuno-Oncology Inc.   Report issue

For profit Phase 1
Founded: Orange County CA United States (2015)

Organization Overview

First Clinical Trial
2019
NCT03989895
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

PrimeVax Immuno-Oncology Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

pv-001-dc (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 1